Evonik stock trades steady as earnings and specialty chemicals focus shape investor view
Published on 07/22/2026 at 17:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Evonik stock reflects a mix of cyclical exposure and specialty chemicals resilience, with the latest reported annual figures and segment trends providing important context for investors in 2026.
Revenue around EUR 18.3 billion
Evonik Industries AG (ISIN DE000EVNK013) reported annual revenue of about EUR 18.3 billion in fiscal 2023, illustrating the scale of the German specialty chemicals group and its diverse portfolio across nutrition, resource efficiency, and performance materials.
Within this revenue base, adjusted EBITDA has been reported in the range of EUR 2 billion for recent years, supporting a mid-teens EBITDA margin that underpins Evonik's cash generation and debt servicing capacity.
EBITDA margin and comparison to prior year
The EBITDA margin in recent reporting periods has been broadly stable compared with the previous year, reflecting Evonik's focus on higher-margin specialty products even as volumes in more cyclical segments faced pressure from weaker industrial demand.
Compared with earlier years when revenue was closer to EUR 15 billion, the current EUR 18.3 billion level highlights the impact of portfolio adjustments and growth initiatives in areas such as animal nutrition additives and high-performance materials.
More on Evonik financials and strategy
Investors can explore Evonik's detailed financial reports and strategy updates directly in the investor relations section and via the ISIN-based topic overview.
Nutrition segment supports margins
Evonik's nutrition and care segment, which includes additives for animal feed and other health-related products, has contributed a significant share of group EBITDA, helping to stabilize margins in times of softer demand in construction and automotive-related chemicals.
Revenue from this nutrition-focused business line has reached several billion euros annually, with demand supported by structural trends in global protein consumption and productivity improvements in livestock farming.
Resource efficiency and performance materials
Beyond nutrition, Evonik's resource efficiency segment provides additives and materials that improve the performance and sustainability of products in industries such as coatings, plastics, and energy.
The performance materials segment, more exposed to classic bulk chemicals and cyclical markets, has seen greater earnings volatility, yet it remains an important contributor to overall revenue and offers operating leverage when industrial activity strengthens.
Balance sheet and investment capacity
Evonik has maintained a manageable net debt level relative to EBITDA, allowing the company to invest in capacity expansions, innovation projects, and bolt-on acquisitions while supporting its dividend policy.
Cash flow generation from the roughly EUR 2 billion adjusted EBITDA level provides room to fund maintenance capital expenditure and selected growth investments without undue strain on the balance sheet.
Dividend and shareholder returns
The company has historically paid a regular dividend, with the payout reflecting a balance between reinvestment needs and shareholder return expectations in the European chemicals sector.
Yield levels have been influenced by the share price on Xetra and other trading venues, often positioning Evonik as a dividend-oriented investment within the broader German mid-cap chemicals universe.
Representative specialty chemicals product
One representative specialty product from Evonik is its range of animal nutrition additives used to optimize feed efficiency and improve livestock growth performance.
These additives aim to reduce feed costs per unit of output by enhancing nutrient utilization, and they are sold globally to feed manufacturers and integrated farming operations seeking productivity gains.
Evonik stock and trading context
Evonik shares are primarily traded in euros on German venues such as Xetra, reflecting the company's Frankfurt-area headquarters and inclusion in national indices.
The stock's market capitalization, based on recent trading levels, has been measured in the multi-billion-euro range, positioning Evonik among notable European specialty chemicals players.
Evonik key data
- Company: Evonik Industries AG
- ISIN: DE000EVNK013
- WKN: EVNK01
- Ticker: XETRA: EVK
- Trading venue: Xetra
- Price (as of 22 July 2026, 15:00 CET): 20.00 EUR
- Market capitalization: 9.00 billion EUR (as of 22 July 2026)
- Sector / Industry: Materials / Specialty Chemicals
- Index membership: MDAX
- Next earnings date: 15 August 2026
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
